Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P03999
UPID:
OPSB_HUMAN
Alternative names:
Blue cone photoreceptor pigment; Blue-sensitive opsin
Alternative UPACC:
P03999; Q13877
Background:
Short-wave-sensitive opsin 1, also known as Blue cone photoreceptor pigment or Blue-sensitive opsin, plays a pivotal role in vision. It is a visual pigment molecule essential for absorbing light and mediating vision, primarily in the blue spectrum. This protein is integral to the maintenance of cone outer segment organization in the ventral retina and ensures the correct abundance and localization of retinal membrane proteins, potentially enhancing spectral sensitivity in low light conditions.
Therapeutic significance:
The association of Short-wave-sensitive opsin 1 with Tritan color blindness, a disorder characterized by a selective deficiency of blue spectral sensitivity, underscores its clinical importance. Understanding the role of Short-wave-sensitive opsin 1 could open doors to potential therapeutic strategies for vision disorders, particularly those affecting color perception.